×

Avadel Pharmaceuticals Reports Third Quarter 2017 Results

Total Revenues for the Third Quarter Were $39.7 Million

Full Year Revenue Guidance of $165-$175 Million Unchanged

Acquired License for Noctiva

DUBLIN, Ireland, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the third quarter ended September 30, 2017.

Highlights Include:

  • Total revenues for the third quarter 2017 were $39.7 million, compared to $32.1 million in the third quarter 2016.

  • GAAP net income for the third quarter of 2017 was $21.7 million, or $0.52 per diluted share, compared to GAAP net loss of $20.0 million, or $0.48 per diluted share, in the third quarter of 2016.

  • Adjusted net income for the third quarter of 2017 was $3.7 million, or $0.09 per diluted share, compared to an adjusted net loss of $3.5 million, or $0.08 per diluted share, in the third quarter of 2016. (1)

  • On September 1, 2017, the Company acquired the commercial license for Noctiva™, the first and only product approved by the U.S. Food & Drug Administration (FDA) for the treatment of nocturia due to nocturnal polyuria in adults.

  • Cash and marketable securities at September 30, 2017 were $115.6 million, down from $173.8 million at June 30, 2017, largely as a result of cash used for the Noctiva license acquisition.

  • Cash used for share repurchases totaled $16.7 million for the nine months ended September 30, 2017.

Mike Anderson, Avadel's Chief Executive Officer, said, "The third quarter of 2017 was another strong quarter for Avadel. Operationally, the Company continues to execute. We have generated $30 million in operating cash flow year-to-date, and we have maintained our full year revenue guidance of $165-$175 million. Our strong financial performance over the last few years has allowed us to invest in the development and acquisition of proprietary specialty products that will provide the Company with long-term growth opportunities."

Mr. Anderson continued, "In early September, we took another step forward in the continued pursuit of becoming a fully integrated specialty pharmaceutical company when we acquired the license to commercialize Noctiva. Noctiva is the first and only product approved by the FDA for the treatment of nocturia, and aligns with our mission to offer patients differentiated specialty products that are safe and effective. We also believe Noctiva is an excellent strategic growth opportunity for Avadel, as it is the only available FDA approved product for this indication and has excellent patent protection through 2030 with the potential to deliver meaningful shareholder value."

Third Quarter 2017 Results

Revenues during the third quarter of 2017 were $39.7 million, compared to $32.1 million during the same period last year. The increase in revenues was due to Akovaz®, which was not fully launched in the third quarter of 2016. However, this increase was partially offset by a decline in Bloxiverz® revenues, primarily as a result of additional competition to neostigmine in the form of an alternative molecule, sugammadex, and continued pricing pressure due to four competing neostigmine products. On a GAAP basis, net income was $21.7 million during the third quarter of 2017, or $0.52 per diluted share, compared to a net loss of $20.0 million, or $0.48 per diluted share, for the same period last year. This increase in net income on a year-over-year basis was attributed to $9.9 million of gains related to changes in the fair value of related party contingent consideration for the third of quarter 2017, compared to $20.8 million of expense in the same period last year. Changes in the fair value of related party contingent consideration are non-cash items, and do not reflect the cash amount paid to related parties. Cash payments can be found in the Consolidated Statement of Cash Flows.

Research and development expenses totaled $8.1 million for the third quarter of 2017, flat compared to the same period last year. Sequentially, research and development expenses were up from $6.8 million in the second quarter of 2017 as a result of increased spend on the REST-ON clinical trial. Research and development expenses are expected to increase in the fourth quarter of 2017 as the Company continues to open clinical sites in the United States and looks to add sites in new countries.

Selling, general and administrative expenses were $11.6 million in the third quarter of 2017, compared to $12.7 million in the same period last year. This decrease was largely due to a lower in stock based compensation expense period over period, partially offset by higher payroll and benefit costs as the Company continues to hire new employees to support future growth of the business.

Adjusted net income for the third quarter of 2017 was $3.7 million, or $0.09 per diluted share, compared to an adjusted net loss of $3.5 million, or $0.08 per diluted share, in the same period last year.(1) The increase in adjusted net income is largely attributable to an increase in revenues from Akovaz® and a lower adjusted effective tax rate of 58% compared to 283% in the prior year period. Please see the Supplemental Information section within this document for a reconciliation of adjusted net income and adjusted diluted EPS to the respective GAAP amounts.

2017 Guidance

The Company reiterated its full year revenue guidance of between $165 and $175 million. During the fourth quarter of 2017, the Company expects to spend approximately $15 million on launch preparation costs for Noctiva, and between $8 to $10 million in research and development costs, principally associated with the REST-ON clinical trial. For the full year, research and development costs are now expected to be in the range of $30 to $35 million and selling, general & administrative costs are expected to be in the range of $60 to $65 million, inclusive of the Noctiva launch preparation costs. As a result of the Noctiva costs, the Company slightly lowered its full year adjusted diluted EPS guidance to $0.25 to $0.35, down from $0.30 to $0.45.

Conference Call

A conference call to discuss these results has been scheduled for Wednesday, November 8, 2017 at 10:00 a.m. EST. A question and answer period will follow management's prepared remarks. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 6289129. A live audio webcast can be accessed by visiting the Investors section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri, United States and Lyon, France. For more information, please visit www.avadel.com.

About Noctiva™
Noctiva is the first and only formulation of desmopressin acetate, a vasopressin analog, approved by the FDA for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected preservative-free intranasal delivery system. Noctiva is dosed as a single spray in one nostril 30 minutes before bedtime, and is approved in two dosage forms of 0.83 mcg and 1.66 mcg. Noctiva is expected to become available to patients in the second quarter of 2018. (Full Prescribing Information available here).

Important Safety Information and Indication for Noctiva (desmopressin acetate)
WARNING: HYPONATREMIA

  • NOCTIVA can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death.

  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.

  • Ensure serum sodium concentrations are normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.

  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.

Safe Harbor: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof, identify forward-looking statements, each of which speaks only as of the date the statement is made. Although we believe that our forward-looking statements are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and our results of operations will not differ materially from the results contemplated in such forward-looking statements. These risks include: (i) risks relating to our license agreement with Serenity Pharmaceuticals, LLC including that our internal analyses may overstate the market opportunity in the United States for the drug desmopressin acetate (the “Drug”) or we may not effectively exploit such market opportunity, that significant safety or drug interaction problems could arise with respect to the Drug, that we may not successfully increase awareness of nocturia and the potential benefits of the Drug, and that the need for management to focus attention on the development and commercialization of the Drug could cause our ongoing business operations to suffer; and (ii) the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2016, in particular under the captions “Forward-Looking Statements” and “Risk Factors,” including without limitation: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz®,Vazculep® and Akovaz® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such products and apply for FDA approval of such products before us; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; and our dependence on key personnel to execute our business plan. Except as may be required by law, we disclaim any obligation to publicly update any forward-looking statements to reflect events after the date of this press release.

Non-GAAP Disclosures and Adjustments

Avadel discloses certain non-GAAP financial measures, including adjusted net income and loss and adjusted net income and loss per diluted share, as management believes that a comparison of its current and historical results would be difficult if the disclosures were limited to financial measures prepared only in accordance with generally accepted accounting principles (GAAP) in the U.S. In addition to reporting its financial results in accordance with GAAP, Avadel reports certain non-GAAP results that exclude, if any, fair value remeasurements of its contingent consideration, impairment of intangible assets, amortization of intangible assets, restructuring costs, foreign exchange gains and losses on assets and liabilities denominated in foreign currencies, but includes the operating cash flows plus any unpaid accrued amounts associated with the contingent consideration, in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. The Company's management uses these non-GAAP measures internally for forecasting, budgeting and measuring its operating performance. Investors and other readers should review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most closely applicable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. The table provided within the following “Supplemental Information” section reconciles GAAP net income and loss and diluted earnings or loss per share to the corresponding adjusted amounts.

___________________________

1Non-GAAP financial measure: Descriptions of Avadel’s non-GAAP financial measures are included under the caption Non-GAAP Disclosures and Adjustments included within this press release and reconciliations of such non-GAAP financial measures to their most closely applicable GAAP financial measures are found in the Supplemental Information section herein.

Contacts:Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
Email: mkanan@avadel.com
Lauren Stival
Sr. Director, Investor Relations & Corporate Communications
Phone: (636) 449-5866
Email: lstival@avadel.com


AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(In thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
2017 2016 2017 2016
Revenues:
Product sales and services $39,147 $31,340 $138,009 $104,858
License and research revenue 528 747 484 2,303
Total 39,675 32,087 138,493 107,161
Operating expenses:
Cost of products and services sold 3,790 2,844 12,253 10,657
Research and development expenses 8,095 8,143 22,093 21,135
Selling, general and administrative expenses 11,563 12,740 35,804 33,491
Intangible asset amortization 564 3,702 1,692 10,918
(Gain)/loss - changes in fair value of related party contingent consideration (9,906) 20,848 (30,107) 52,989
Restructuring (income) costs (549) 3,173
Total operating expenses 13,557 48,277 44,908 129,190
Operating income (loss) 26,118 (16,190) 93,585 (22,029)
Investment income, net 1,110 490 2,689 1,080
Interest expense, net (263) (264) (789) (702)
Other income (expense) - changes in fair value of related party payable 768 (1,828) 2,988 (6,135)
Foreign exchange gain (loss) (133) 1,249 (127) (12)
Income (loss) before income taxes 27,600 (16,543) 98,346 (27,798)
Income tax provision 5,921 3,451 21,830 18,212
Net income (loss) $21,679 $(19,994) $76,516 $(46,010)
Net income (loss) per share - basic $0.54 $(0.48) $1.87 $(1.12)
Net income (loss) per share - diluted 0.52 (0.48) 1.81 (1.12)
Weighted average number of shares outstanding - basic 40,061 41,241 40,839 41,241
Weighted average number of shares outstanding - diluted 41,339 41,241 42,194 41,241


AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
September 30, 2017 December 31, 2016
ASSETS
Current assets:
Cash and cash equivalents $37,449 $39,215
Marketable securities 78,161 114,980
Accounts receivable 24,080 17,839
Inventories, net 5,870 3,258
Prepaid expenses and other current assets 3,373 5,894
Total current assets 148,933 181,186
Property and equipment, net 3,180 3,320
Goodwill 18,491 18,491
Intangible assets, net 94,256 22,837
Research and development tax credit receivable 3,547 1,775
Income tax deferred charge 10,342
Other 9,020 7,531
Total assets $277,427 $245,482
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $301 $268
Current portion of long-term related party payable 30,986 34,177
Accounts payable 8,564 7,105
Deferred revenue 1,927 2,223
Accrued expenses 47,997 17,222
Income taxes 7,026 1,200
Other 507 226
Total current liabilities 97,308 62,421
Long-term debt, less current portion 614 547
Long-term related party payable, less current portion 76,131 135,170
Other 6,911 5,275
Total liabilities 180,964 203,413
Shareholders' equity:
Preferred shares, $0.01 nominal value; 50,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016, respectively
Ordinary shares, nominal value of $0.01; 500,000 shares authorized; 41,435 and 41,371 issued and outstanding at September 30, 2017 and December 31, 2016, respectively 414 414
Treasury shares, at cost, 1,673 and 0 shares held at September 30, 2017 and December 31, 2016, respectively (17,506)
Additional paid-in capital 391,416 385,020
Accumulated deficit (254,440) (319,800)
Accumulated other comprehensive loss (23,421) (23,565)
Total shareholders' equity 96,463 42,069
Total liabilities and shareholders' equity $277,427 $245,482


AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Nine Months Ended September 30,
2017 2016
Cash flows from operating activities:
Net income (loss) 76,516 (46,010)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 2,664 11,555
Loss on disposal of property and equipment 110
Loss (gain) on sale of marketable securities (550) 666
Foreign exchange loss 127 12
Grants recognized in research and development expenses (70)
Remeasurement of related party acquisition-related contingent consideration (30,107) 52,989
Remeasurement of related party financing-related contingent consideration (2,988) 6,135
Change in deferred tax and income tax deferred charge 322 (5,680)
Stock-based compensation expense 6,019 10,541
Increase (decrease) in cash from:
Accounts receivable (6,240) (7,594)
Inventories (2,612) 2,080
Prepaid expenses and other current assets 1,924 671
Research and development tax credit receivable (1,576) (1,794)
Accounts payable & other current liabilities 804 1,291
Deferred revenue (283) (2,198)
Accrued expenses 9,324 2,700
Accrued income taxes 5,826
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value (24,729) (14,486)
Royalty payments for related party payable in excess of original fair value (3,446) (1,790)
Other long-term assets and liabilities (517) 2,032
Net cash provided by operating activities 30,478 11,160
Cash flows from investing activities:
Purchases of property and equipment (533) (1,000)
Acquisitions of businesses 628
Purchase of intangible assets (52,139)
Proceeds from sales of marketable securities 153,398 46,483
Purchases of marketable securities (115,893) (96,199)
Net cash used in investing activities (15,167) (50,088)
Cash flows from financing activities:
Earn-out payments for related party contingent consideration (961) (6,834)
Royalty payments for related party payable (1,117)
Reimbursement of loans (61)
Cash proceeds from issuance of ordinary shares and warrants 376
Share repurchases (16,707)
Net cash used in financing activities (17,292) (8,012)
Effect of foreign currency exchange rate changes on cash and cash equivalents 215 656
Net decrease in cash and cash equivalents (1,766) (46,284)
Cash and cash equivalents at January 1, 39,215 65,064
Cash and cash equivalents at September 30, $37,449 $18,780


AVADEL PHARMACEUTICALS PLC
UNAUDITED SUPPLEMENTAL INFORMATION
(In thousands, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
Revenues by Product: 2017 2016 2017 2016
Bloxiverz $9,920 $15,591 $37,541 $65,958
Vazculep 9,573 9,340 29,906 29,167
Akovaz 18,561 5,568 65,110 5,568
Other 1,093 841 5,452 4,165
Total product sales and services 39,147 31,340 138,009 104,858
License and research revenue 528 747 484 2,303
Total revenues $39,675 $32,087 $138,493 $107,161


GAAP to Non-GAAP adjustments for the three-months ended September 30, 2017
Exclude Include
GAAP Intangible asset amortization Foreign exchange (gain)/loss Restructuring impacts Contingent related party payable fair value adjustment Contingent related party payable paid/accrued Total adjustments Adjusted GAAP
Revenues:
Product sales and services $39,147 $ $ $ $ $ $ $39,147
License and research revenue 528 528
Total 39,675 39,675
Operating expenses:
Cost of products and services sold 3,790 3,790
Research and development 8,095 8,095
Selling, general and administrative 11,563 11,563
Intangible asset amortization 564 (564) (564)
Changes in fair value of related party contingent consideration (9,906) 9,906 7,264 17,170 7,264
Restructuring costs (549) 549 549
Total 13,557 (564) 549 9,906 7,264 17,155 30,712
Operating income (loss) 26,118 564 (549) (9,906) (7,264) (17,155) 8,963
Investment and other income 1,110 1,110
Interest expense (263) (263)
Other expense - changes in fair value of related party payable 768 (768) (963) (1,731) (963)
Foreign exchange gain (133) 133 133
Income (loss) before income taxes 27,600 564 133 (549) (10,674) (8,227) (18,753) 8,847
Income tax provision (benefit) 5,921 201 (507) (515) (821) 5,100
Net income (loss) $21,679 $363 $133 $(549) $(10,167) $(7,712) $(17,932) $3,747
Net income (loss) per share - diluted(1) 0.52 $0.01 $ $(0.01) $(0.25) $(0.19) $(0.43) $0.09
Weighted average number of shares outstanding - diluted 41,339 41,339 41,339 41,339 41,339 41,339 41,339 41,339

(1) Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

GAAP to Non-GAAP adjustments for the three-months ended September 30, 2016
Exclude Include
GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value adjustment Contingent related party payable paid/accrued Total adjustments Adjusted GAAP
Revenues:
Product sales and services $31,340 $ $ $ $ $ $31,340
License and research revenue 747 747
Total 32,087 32,087
Operating expenses:
Cost of products and services sold 2,844 2,844
Research and development 8,143 8,143
Selling, general and administrative 12,740 12,740
Intangible asset amortization 3,702 (3,702) (3,702)
Changes in fair value of related party contingent consideration 20,848 (20,848) 5,884 (14,964) 5,884
Restructuring costs
Total 48,277 (3,702) (20,848) 5,884 (18,666) 29,611
Operating income (loss) (16,190) 3,702 20,848 (5,884) 18,666 2,476
Investment and other income 490 490
Interest expense (264) (264)
Other expense - changes in fair value of related party payable (1,828) 1,828 (785) 1,043 (785)
Foreign exchange gain 1,249 (1,249) (1,249)
Income (loss) before income taxes (16,543) 3,702 (1,249) 22,676 (6,669) 18,460 1,917
Income tax provision (benefit) 3,451 1,329 1,021 (385) 1,965 5,416
Net income (loss) $(19,994) $2,373 $(1,249) $21,655 $(6,284) $16,495 $(3,499)
Net income (loss) per share - diluted(1) (0.48) $0.06 $(0.03) $0.53 $(0.15) $0.40 $(0.08)
Weighted average number of shares outstanding - diluted 41,241 41,241 41,241 41,241 41,241 41,241 41,241

(1) Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

GAAP to Non-GAAP adjustments for the nine-months ended September 30, 2017
Exclude Include
GAAP Intangible asset amortization Foreign exchange (gain)/loss Restructuring impacts Purchase accounting adjustment - FSC License revenue Contingent related party payable fair value adjustment Contingent related party payable paid/accrued Total adjustments Adjusted GAAP
adjustment
Revenues:
Product sales and services $138,009 $ $ $ $ $ $ $ $ $138,009
License and research revenue 484 1,100 1,100 1,584
Total 138,493 1,100 1,100 139,593
Operating expenses:
Cost of products and services sold 12,253 (46) (46) 12,207
Research and development 22,093 22,093
Selling, general and administrative 35,804 35,804
Intangible asset amortization 1,692 (1,692) (1,692)
Changes in fair value of related party contingent consideration (30,107) 30,107 25,396 55,503 25,396
Restructuring charges 3,173 (3,173) (3,173)
Total 44,908 (1,692) (3,173) (46) 30,107 25,396 50,592 95,500
Operating income (loss) 93,585 1,692 3,173 46 1,100 (30,107) (25,396) (49,492) 44,093
Investment and other income 2,689 2,689
Interest expense (789) (789)
Other expense - changes in fair value of related party payable 2,988 (2,988) (3,428) (6,416) (3,428)
Foreign exchange gain (127) 127 127
Income (loss) before income taxes 98,346 1,692 127 3,173 46 1,100 (33,095) (28,824) (55,781) 42,565
Income tax provision (benefit) 21,830 603 17 (1,776) (1,822) (2,978) 18,852
Net income (loss) $76,516 $1,089 $127 $3,173 $29 $1,100 $(31,319) $(27,002) $(52,803) $23,713
Net income (loss) per share - diluted(1) 1.81 $0.03 $ $0.08 $ $0.03 $(0.74) $(0.64) $(1.25) $0.56
Weighted average number of shares outstanding - diluted 42,194 42,194 42,194 42,194 42,194 42,194 42,194 42,194 42,194 42,194

(1) Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

GAAP to Non-GAAP adjustments for the nine-months ended September 30, 2016
Exclude Include
GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent related party payable fair value adjustment Contingent related party payable paid/accrued Total adjustments Adjusted GAAP
Revenues:
Product sales and services $104,858 $ $ $ $ $ $ $104,858
License and research revenue 2,303 2,303
Total 107,161 107,161
Operating expenses:
Cost of products and services sold 10,657 (1,525) (1,525) 9,132
Research and development 21,135 21,135
Selling, general and administrative 33,491 33,491
Intangible asset amortization 10,918 (10,918) (10,918)
Changes in fair value of related party contingent consideration 52,989 (52,989) 19,321 (33,668) 19,321
Total 129,190 (10,918) (1,525) (52,989) 19,321 (46,111) 83,079
Operating income (loss) (22,029) 10,918 1,525 52,989 (19,321) 46,111 24,082
Investment and other income 1,080 1,080
Interest expense (702) (702)
Other expense - changes in fair value of related party payable (6,135) 6,135 (2,618) 3,517 (2,618)
Foreign exchange gain (12) 12 12
Income (loss) before income taxes (27,798) 10,918 12 1,525 59,124 (21,939) 49,640 21,842
Income tax provision (benefit) 18,212 3,920 533 2,986 (1,165) 6,274 24,486
Net income (loss) $(46,010) $6,998 $12 $992 $56,138 $(20,774) $43,366 $(2,644)
Net income (loss) per share - diluted(1) (1.12) $0.17 $ $0.02 $1.36 $(0.50) $1.05 $(0.07)
Weighted average number of shares outstanding - diluted 41,241 41,241 41,241 41,241 41,241 41,241 41,241 41,241

(1) Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

Source:Avadel Pharmaceuticals plc